Bigora Sian 4

4 · Processa Pharmaceuticals, Inc. · Filed Aug 2, 2024

Form 4

Period: 2024-04-05

Chief Development Officer

Transactions

Tax Payment
Common Stock
2024-07-10$1.71/sh−225$385→ 21,878 total
Exercise/Conversion
Common Stock
2024-04-05+1,675→ 21,827 total
Tax Payment
Common Stock
2024-04-05$2.79/sh−368$1,027→ 21,459 total
Exercise/Conversion
Common Stock
2024-07-10+644→ 22,103 total
Award
Restricted Stock Units
2024-06-28+3,233→ 24,728 total
Exercise: $0.00→ Common Stock (3,233 underlying)
Award
Restricted Stock Units
2024-06-28+404→ 27,961 total
Exercise: $0.00→ Common Stock (404 underlying)
Award
Restricted Stock Units
2024-06-28+2,425→ 27,153 total
Exercise: $0.00→ Common Stock (2,425 underlying)
Award
Restricted Stock Units
2024-06-28+404→ 27,557 total
Exercise: $0.00→ Common Stock (404 underlying)

Holdings

Footnotes (4)

[F1]Distribution of vested restricted shares.
[F2]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.
[F3]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.
[F4]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

Documents

1 file